March 2, 2026: Gastrointestinal Lawsuits Involving Trulicity, Other GLP-1s Increase in March Eli Lilly and one other drug company are facing 3,363 lawsuits in a consolidated MDL, in which plaintiffs accuse the companies of failing to warn patients about the gastrointestinal risks of taking Trulicity and other GLP-1s
But, with so much information available, it can be challenging to determine which acid is the right fit for your unique skin type and concerns
They found that the significantly enhanced expression of NLRP1, NLRP3, NLRC4, AIM2, ASC, caspase-1, pre-IL-1, pre-IL-18, mRNA and protein in thyroid tissue of HT patients [28]
This differs from the approved low-dose titration schedules (such as starting semaglutide at 0.25mg) that manufacturers recommend to improve tolerability